Diagnostic Confirmation and Management of Hodgkin Lymphoma

Rationale for Diagnostic Confirmation

The European Hematology Association recommends obtaining definitive tissue diagnosis through excisional lymph node biopsy or core needle biopsy to confirm Hodgkin lymphoma before initiating any lymphoma-directed therapy, as bone marrow findings are highly suggestive but not diagnostic 1.

The American Society of Hematology suggests monitoring complete blood counts daily to track the progression of pancytopenia, particularly the absolute neutrophil count and platelet count 1.
The National Comprehensive Cancer Network recommends assessing for active infection given the fever, splenomegaly, and borderline leukopenia—obtaining blood cultures, chest imaging, and considering empiric broad-spectrum antibiotics if absolute neutrophil count falls below 1.0 × 10⁹/L or clinical deterioration occurs 1.

The European Society for Medical Oncology strongly recommends a CT scan of neck, chest, abdomen, and pelvis for volumetric assessment and identification of bulky disease (mediastinal mass >1/3 maximum horizontal thoracic diameter) 1, 2.
The American College of Radiology suggests that FDG-PET scan is strongly recommended for accurate staging and baseline assessment, as it will be critical for response evaluation 1, 3.
The American Heart Association recommends cardiac and pulmonary function testing (echocardiogram or MUGA scan, pulmonary function tests) to identify patients at increased risk of treatment-related complications, particularly given the planned use of doxorubicin and bleomycin in ABVD 1, 2.

The American Society of Clinical Oncology advises against initiating chemotherapy based solely on bone marrow findings without lymph node confirmation, as this significantly increases treatment-related mortality 1.

The National Comprehensive Cancer Network recommends that once diagnosis is confirmed and staging completed, treatment should not be delayed if the patient remains clinically stable with supportive care, with 6-8 cycles of ABVD chemotherapy being the standard treatment for advanced-stage disease 1, 3, 2.

The American Society for Reproductive Medicine recommends that reproductive counseling must be offered immediately before any treatment initiation, as chemotherapy and radiotherapy cause permanent fertility damage 1, 2.

Bone‑marrow biopsy is mandatory in patients presenting with severe pancytopenia and abnormal blood counts to differentiate marrow infiltration by Hodgkin lymphoma from other causes. 4, 5, 6, 7, 8
Comprehensive laboratory panel (including ESR, LDH, albumin, hepatic and renal function tests) should be obtained to enable risk stratification and calculation of the International Prognostic Score (IPS). 4, 5, 6, 7, 8

Pre‑chemotherapy cardiac evaluation (echocardiogram or MUGA scan) and pulmonary function testing are required because the standard ABVD regimen contains doxorubicin (cardiotoxic) and bleomycin (pulmonary toxic). 4, 5
Assessment of left‑ventricular ejection fraction is specifically recommended to identify patients at heightened risk for treatment‑related cardiac complications. 4, 5
Baseline thyroid function testing should be documented and optimized before initiating chemotherapy, especially in patients with known hypothyroidism. 4, 5, 7, 8

Six cycles of ABVD chemotherapy remain the standard first‑line regimen for advanced‑stage Hodgkin lymphoma in patients older than 60 years. 4, 5, 7
Escalated BEACOPP is not recommended for patients over 60 years with significant comorbidities; it should only be considered when the IPS is ≥ 4 and even then a modified approach is preferred. 4, 7, 9
An initial dose‑reduced ABVD (approximately 75 % of full dose) may be employed in the setting of severe baseline cytopenias, low body weight, and multiple comorbidities, with subsequent dose escalation based on tolerance. 9

Mandatory hematology‑oncology consultation is required for treatment planning in patients with severe cytopenias and complex comorbid conditions. 9